BR112018068072A2 - uso e combinação de quantidades terapeuticamente eficazes de (a) (i) vitamina c e/ou selênio e (ii) pelo menos um dentre ácido docosa-hexaenoico, ácido eicosapentaenoico e ácido docosapentaenoico, ou seus ésteres; ou (b) (i) vitamina c e/ou selênio e (iii) uma ou mais dentre uridina e citidina, seus sais, fosfatos, derivados de acila ou ésteres; ou (c) uma combinação de (i), (ii) e (iii); composição para uso no aprimoramento terapêutico da função cognitiva e/ou de memória em pacientes humanos dela necessitados, e método de aprimoramento (não terapêutico) da função cognitiva e/ou função de memória em pacientes humanos saudáveis dele necessitados - Google Patents
uso e combinação de quantidades terapeuticamente eficazes de (a) (i) vitamina c e/ou selênio e (ii) pelo menos um dentre ácido docosa-hexaenoico, ácido eicosapentaenoico e ácido docosapentaenoico, ou seus ésteres; ou (b) (i) vitamina c e/ou selênio e (iii) uma ou mais dentre uridina e citidina, seus sais, fosfatos, derivados de acila ou ésteres; ou (c) uma combinação de (i), (ii) e (iii); composição para uso no aprimoramento terapêutico da função cognitiva e/ou de memória em pacientes humanos dela necessitados, e método de aprimoramento (não terapêutico) da função cognitiva e/ou função de memória em pacientes humanos saudáveis dele necessitadosInfo
- Publication number
- BR112018068072A2 BR112018068072A2 BR112018068072A BR112018068072A BR112018068072A2 BR 112018068072 A2 BR112018068072 A2 BR 112018068072A2 BR 112018068072 A BR112018068072 A BR 112018068072A BR 112018068072 A BR112018068072 A BR 112018068072A BR 112018068072 A2 BR112018068072 A2 BR 112018068072A2
- Authority
- BR
- Brazil
- Prior art keywords
- vitamin
- selenium
- esters
- iii
- combination
- Prior art date
Links
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract 5
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 title abstract 4
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 title abstract 4
- MBMBGCFOFBJSGT-KUBAVDMBSA-N all-cis-docosa-4,7,10,13,16,19-hexaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 title abstract 4
- 150000002148 esters Chemical class 0.000 title abstract 4
- 229910052711 selenium Inorganic materials 0.000 title abstract 4
- 239000011669 selenium Substances 0.000 title abstract 4
- 230000001225 therapeutic effect Effects 0.000 title abstract 4
- 229960005070 ascorbic acid Drugs 0.000 title abstract 3
- 230000003920 cognitive function Effects 0.000 title abstract 3
- 230000006386 memory function Effects 0.000 title abstract 3
- YUFFSWGQGVEMMI-JLNKQSITSA-N (7Z,10Z,13Z,16Z,19Z)-docosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCCCC(O)=O YUFFSWGQGVEMMI-JLNKQSITSA-N 0.000 title abstract 2
- UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 title abstract 2
- UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 title abstract 2
- 235000021294 Docosapentaenoic acid Nutrition 0.000 title abstract 2
- 229910019142 PO4 Inorganic materials 0.000 title abstract 2
- 125000002252 acyl group Chemical group 0.000 title abstract 2
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 title abstract 2
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 title abstract 2
- UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 title abstract 2
- 235000020669 docosahexaenoic acid Nutrition 0.000 title abstract 2
- 229940090949 docosahexaenoic acid Drugs 0.000 title abstract 2
- 235000020673 eicosapentaenoic acid Nutrition 0.000 title abstract 2
- 229960005135 eicosapentaenoic acid Drugs 0.000 title abstract 2
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 title abstract 2
- 235000021317 phosphate Nutrition 0.000 title abstract 2
- 150000003013 phosphoric acid derivatives Chemical class 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 title abstract 2
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 title abstract 2
- 229940045145 uridine Drugs 0.000 title abstract 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
- 229930003268 Vitamin C Natural products 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000000946 synaptic effect Effects 0.000 abstract 1
- 229930003231 vitamin Natural products 0.000 abstract 1
- 229940088594 vitamin Drugs 0.000 abstract 1
- 235000013343 vitamin Nutrition 0.000 abstract 1
- 239000011782 vitamin Substances 0.000 abstract 1
- 235000019154 vitamin C Nutrition 0.000 abstract 1
- 239000011718 vitamin C Substances 0.000 abstract 1
- 150000003722 vitamin derivatives Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/04—Nitro compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
a presente invenção refere-se ao uso de quantidades terapeuticamente eficazes de (a) (i) vitamina c e/ou selênio e (ii) pelo menos um dentre ácido docosa-hexaenoico (22:6; dha), ácido eicosapentaenoico (20:5; epa) e ácido docosapentaenoico (22:5; dpa) ou seus ésteres; ou (b) (i) vitamina c e/ou selênio e (iii) uma ou mais dentre uridina e citidina, seus sais, fosfatos, derivados de acila ou ésteres; ou (c) uma combinação de (i), (ii) e (iii); em que (a), (b) ou (c) opcionalmente compreende adicionalmente vitamina e, na fabricação de produtos para aprimoramento terapêutico da conectividade sináptica e/ou sustentação terapêutica da função cognitiva e/ou de memória em pacientes humanos deles necessitados.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/NL2016/050161 WO2017155387A1 (en) | 2016-03-08 | 2016-03-08 | Method for supporting memory function and/or cognitive function |
| PCT/NL2017/050140 WO2017155395A1 (en) | 2016-03-08 | 2017-03-08 | Method for supporting memory function and/or cognitive function |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018068072A2 true BR112018068072A2 (pt) | 2019-01-08 |
Family
ID=55861106
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018068072A BR112018068072A2 (pt) | 2016-03-08 | 2017-03-08 | uso e combinação de quantidades terapeuticamente eficazes de (a) (i) vitamina c e/ou selênio e (ii) pelo menos um dentre ácido docosa-hexaenoico, ácido eicosapentaenoico e ácido docosapentaenoico, ou seus ésteres; ou (b) (i) vitamina c e/ou selênio e (iii) uma ou mais dentre uridina e citidina, seus sais, fosfatos, derivados de acila ou ésteres; ou (c) uma combinação de (i), (ii) e (iii); composição para uso no aprimoramento terapêutico da função cognitiva e/ou de memória em pacientes humanos dela necessitados, e método de aprimoramento (não terapêutico) da função cognitiva e/ou função de memória em pacientes humanos saudáveis dele necessitados |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US11123306B2 (pt) |
| EP (2) | EP4285992A3 (pt) |
| JP (2) | JP7000336B2 (pt) |
| CN (1) | CN109069446A (pt) |
| BR (1) | BR112018068072A2 (pt) |
| ES (1) | ES2965339T3 (pt) |
| FI (1) | FI3426236T3 (pt) |
| HR (1) | HRP20231584T1 (pt) |
| PL (1) | PL3426236T3 (pt) |
| PT (1) | PT3426236T (pt) |
| SI (1) | SI3426236T1 (pt) |
| WO (2) | WO2017155387A1 (pt) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023041776A1 (en) | 2021-09-17 | 2023-03-23 | N.V. Nutricia | Solid composition suitable as a nutritional composition or supplement for animals that suffer from brain related disorders, decline or diseases |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002088129A1 (en) | 2001-04-26 | 2002-11-07 | Wyeth | Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline |
| PL209031B1 (pl) | 2001-04-30 | 2011-07-29 | Trommsdorff Arzneimittel | Estry urydyny, ich zastosowanie i sposób wytwarzania, oraz kompozycje farmaceutyczne je zawierające |
| NL1019368C2 (nl) | 2001-11-14 | 2003-05-20 | Nutricia Nv | Preparaat voor het verbeteren van receptorwerking. |
| AU2006251569B2 (en) * | 2005-05-23 | 2012-06-21 | Massachusetts Institute Of Technology | Compostions containing pufa and/or uridine and methods of use thereof |
| ATE509624T1 (de) * | 2005-12-23 | 2011-06-15 | Nutricia Nv | Zusammensetzung enthaltend mehrfach ungesättigte fettsäuren, proteine, mangan und/oder molybden und nukleotide/nukleoside, zur behandlung von demenz |
| WO2009002145A1 (en) * | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Lipid composition for improving function of brain functioning |
| WO2009002148A1 (en) * | 2007-06-27 | 2008-12-31 | N.V. Nutricia | Food composition for prodromal dementia patients |
| WO2009002146A1 (en) | 2007-06-26 | 2008-12-31 | N.V. Nutricia | Supporting activities of daily living |
| PL2609812T3 (pl) * | 2007-12-20 | 2019-02-28 | N.V. Nutricia | Ciekły produkt zawierający nukleotydy/nukleozydy |
| WO2012125020A1 (en) | 2011-03-14 | 2012-09-20 | N.V. Nutricia | Method for treating neurotrauma |
| WO2013066152A1 (en) * | 2011-10-31 | 2013-05-10 | N.V. Nutricia | Method for improving executive function |
| WO2013129914A1 (en) * | 2012-03-02 | 2013-09-06 | N.V. Nutricia | Method for improving functional synaptic connectivity |
| CN104144691A (zh) * | 2012-03-02 | 2014-11-12 | N·V·努特里奇亚 | 改善功能突触连通性的方法 |
| WO2013149384A1 (en) * | 2012-04-05 | 2013-10-10 | Nippon Suisan Kaisha, Ltd. | Brain atrophy prevention agent |
| GB201405033D0 (en) * | 2014-03-20 | 2014-05-07 | Isis Innovation | Combination therapy |
| WO2016083362A1 (en) * | 2014-11-25 | 2016-06-02 | Fonden For Helene Elsass Centeret | Composition for improving cognitive functions |
-
2016
- 2016-03-08 WO PCT/NL2016/050161 patent/WO2017155387A1/en active Application Filing
-
2017
- 2017-03-08 BR BR112018068072A patent/BR112018068072A2/pt not_active Application Discontinuation
- 2017-03-08 CN CN201780028115.3A patent/CN109069446A/zh active Pending
- 2017-03-08 ES ES17716066T patent/ES2965339T3/es active Active
- 2017-03-08 PT PT177160660T patent/PT3426236T/pt unknown
- 2017-03-08 WO PCT/NL2017/050140 patent/WO2017155395A1/en active Application Filing
- 2017-03-08 EP EP23191395.5A patent/EP4285992A3/en active Pending
- 2017-03-08 SI SI201731457T patent/SI3426236T1/sl unknown
- 2017-03-08 HR HRP20231584TT patent/HRP20231584T1/hr unknown
- 2017-03-08 PL PL17716066.0T patent/PL3426236T3/pl unknown
- 2017-03-08 FI FIEP17716066.0T patent/FI3426236T3/fi active
- 2017-03-08 EP EP17716066.0A patent/EP3426236B1/en active Active
- 2017-03-08 JP JP2018547886A patent/JP7000336B2/ja active Active
- 2017-03-08 US US16/083,399 patent/US11123306B2/en active Active
-
2021
- 2021-08-11 US US17/399,160 patent/US11918546B2/en active Active
- 2021-12-23 JP JP2021208951A patent/JP7230166B2/ja active Active
-
2024
- 2024-01-23 US US18/419,590 patent/US20240156748A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SI3426236T1 (sl) | 2024-02-29 |
| US20240156748A1 (en) | 2024-05-16 |
| JP7230166B2 (ja) | 2023-02-28 |
| JP7000336B2 (ja) | 2022-02-04 |
| US11123306B2 (en) | 2021-09-21 |
| CN109069446A (zh) | 2018-12-21 |
| EP3426236B1 (en) | 2023-10-04 |
| WO2017155387A1 (en) | 2017-09-14 |
| PL3426236T3 (pl) | 2024-03-18 |
| US20190070126A1 (en) | 2019-03-07 |
| EP4285992A3 (en) | 2024-03-06 |
| EP4285992A2 (en) | 2023-12-06 |
| ES2965339T3 (es) | 2024-04-12 |
| US11918546B2 (en) | 2024-03-05 |
| WO2017155395A1 (en) | 2017-09-14 |
| JP2019512487A (ja) | 2019-05-16 |
| JP2022058393A (ja) | 2022-04-12 |
| EP3426236A1 (en) | 2019-01-16 |
| PT3426236T (pt) | 2023-12-04 |
| HRP20231584T1 (hr) | 2024-03-15 |
| US20210386682A1 (en) | 2021-12-16 |
| FI3426236T3 (fi) | 2023-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112014020177A8 (pt) | Uso de uma composição para a fabricação de um produto para diminuir, prevenir ou reverter a conectividade cerebral funcional prejudicada e/ou organização da rede cerebral prejudicada | |
| MX2018003636A (es) | Composicion de uridina y citidina para su uso en la prevencion o tratamiento de neurotrauma. | |
| BRPI0606766A2 (pt) | produtos nutricionais para tratamento dos sintomas da artrite reumatóide | |
| NZ600740A (en) | Compositions containing pufa and/or uridine and methods of use thereof | |
| NZ600167A (en) | Concentrated therapeutic phospholipid compositions | |
| NZ709083A (en) | Eicosapentaenoic acid (epa) formulations | |
| BRPI1011089A8 (pt) | Composição nutricional para estimular o desenvolvimento e a função cerebral de crianças. | |
| MX2016004487A (es) | Capsulas blandas de capa entérica que constan de ácidos grasos poli insaturados. | |
| BR112018014545A2 (pt) | probióticos para uso como agentes anti-inflamatórios na cavidade oral | |
| Kumar et al. | Omega-3 Fatty acids could alleviate the risks of traumatic brain injury–a mini review | |
| NO20074318L (no) | Anvendelse av en fettsyresammensetning som inneholder DHA for fremstilling av et medisinsk produkt eller et naeringsmiddel for behandling av amyloidoserelaterte sykdommer | |
| WO2016040570A3 (en) | Dietary emulsion formulations and methods for using the same | |
| BR112018000242A2 (pt) | composições nutricionais contendo fosfatidiletanolamina, esfingomielina e ácido doco-saexaenóico | |
| BR112015020671A2 (pt) | método de aumentar a biodisponibilidade da dha e outros nutrientes solúveis em lipídeos | |
| BR112015029897A2 (pt) | composição sólida para administração oral contendo ácido ibandrônico ou um seu sal farmaceuticamente aceitável e vitamina d e processo para obtenção da referida composição | |
| BR112018068110A2 (pt) | uso de quantidades terapeuticamente eficazes de uma ou mais dentre uridina e citidina, composição para uso em prevenção terapêutica e/ou redução da velocidade de atrofia cerebral em pacientes humanos dela necessitados, combinação de quantidades terapeuticamente eficazes de uma ou mais dentre uridina e citidina e método de prevenção e/ou redução da velocidade de atrofia cerebral em pacientes humanos que sofrem de atrofia cerebral | |
| GEP201606568B (en) | Compositions for the treatment of neurologic disorders | |
| HRP20201221T1 (hr) | Sastavi omega 3 masnih kiselina za liječenje bolesti koje uključuju štete nastale u živčanom sustavu | |
| BR112021026374A2 (pt) | Composição de cbd | |
| BR112018000236A2 (pt) | composições nutricionais e métodos para a promoção do desenvolvimento cognitivo | |
| BR112015026207A2 (pt) | uso de uma preparação na fabricação de uma composição nutricional, composição nutricional, uso de uma composição nutricional, uso de uma composição, composição, e método para tratamento ou fornecimento de gerenciamento nutricional de pacientes com hiperfenilalaninemia e/ou pacientes com fenilcetonúria | |
| EA201791885A1 (ru) | Смесь жирных кислот и её применение для лечения воспалительных патологий | |
| BR112017007428A2 (pt) | composições de éster de ácido graxo e ácidos graxos autocomnizantes e suas utilizações no tratamento de estados da doença | |
| BR112013026487A2 (pt) | composição, e, método para intensificar o efeito de um agente quimioterapêutico | |
| BR112017027909A2 (pt) | composição, e, uso de uma composição |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07G | Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09B | Patent application refused [chapter 9.2 patent gazette] |